Core Insights - The 2025 Hong Kong International Traditional Chinese Medicine Conference has commenced, focusing on promoting the high-quality global development of traditional Chinese medicine (TCM) [1] - The event gathered nearly 500 experts, scholars, and industry leaders from various regions, showcasing the practical value and development prospects of TCM through diverse activities [1][4] - The conference aims to explore new paths and opportunities for the internationalization of TCM, emphasizing collaboration among government, industry, academia, and research sectors [1] Group 1: Event Overview - The conference features a variety of activities, including rare herbal exhibitions, cultural experiences, product showcases, and lectures by renowned doctors, providing a platform for extensive communication [1][4] - The opening ceremony included a performance of "Ba Duan Jin" and Tai Chi, demonstrating the practicality of TCM in daily health management [4][6] Group 2: Key Speakers and Their Messages - Xu Zhengzhong, Chairman of the Zijing Cultural Group, highlighted TCM as a treasure of the Chinese nation, emphasizing its integration into Hong Kong's healthcare system and its role in the Greater Bay Area [8] - Liang Zhenying, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference, noted that Hong Kong's TCM sector has developed a complete and advanced system, integrating into the overall healthcare and wellness system [10] - Jia Zhongwu, Director of the Comprehensive Department of the National Administration of Traditional Chinese Medicine, stated that the Chinese government places high importance on the development of TCM, promoting its unique advantages in health initiatives [12] Group 3: Government Support and Future Directions - Chen Guoki, Secretary for Administration of the Hong Kong SAR Government, expressed the government's commitment to promoting high-quality TCM development, leveraging Hong Kong's unique advantages [15] - Wang Cuijun, General Manager of China Resources Group, emphasized the global collaboration needed for TCM's innovation and its role in building a healthy community [17] - The conference also launched the "High-Quality Development of the Traditional Chinese Medicine Industry Chain" initiative, aiming to foster collaborative development and cultural dissemination of TCM [21] Group 4: Conference Activities and Impact - The conference will last four days, featuring exhibitions, international summits, and community health services, showcasing TCM's cultural charm and development achievements [23] - The event aims to contribute to human health and well-being by promoting the innovative and open development of TCM [23]

Core Points - The "2025 Hong Kong International Traditional Chinese Medicine Conference" commenced in Hong Kong, focusing on promoting the high-quality global development of traditional Chinese medicine (TCM) [2][23] - The event gathered nearly 500 experts, scholars, and industry leaders from various regions, including over 130 exhibiting organizations, showcasing the practical value and development prospects of TCM [2][23] - The conference featured diverse activities such as rare herbal exhibitions, cultural experiences, product showcases, and lectures by renowned doctors, facilitating discussions on the internationalization of TCM [2][23] Group 1: Event Overview - The conference opened with a half-hour performance of "Ba Duan Jin" and Tai Chi, integrating traditional practices into modern urban life, which received enthusiastic responses from attendees [2][3] - Key figures in attendance included national and local government officials, industry leaders, and TCM experts, highlighting the significance of the event [4][6][9] Group 2: Government and Industry Support - The chairman of the organizing group emphasized TCM as a treasure of the Chinese nation, supported by the Hong Kong government through initiatives like establishing TCM hospitals and research centers [6][14] - The Hong Kong government is committed to promoting high-quality TCM development, leveraging its unique advantages in cultural resources and international medical systems [14][16] Group 3: Collaborative Initiatives - A "High-Quality Development of the Chinese Medicine Industry Chain and Cultural Co-Link Initiative" was launched, with representatives from major companies signing to promote collaborative development and cultural dissemination of TCM [21] - The conference aims to serve as a platform for global cooperation in TCM, enhancing product development, talent exchange, and market expansion [19][21] Group 4: Future Activities - The conference will last four days, featuring exhibitions, international summits, and community health services, showcasing TCM's cultural charm and development achievements [23]

【导读】 2025香港国际中医药大会在港启幕，以全球智慧共谋中医药高质量走向世 中国基金报记者 郭玟君 9月25日，由紫荆文化集团主办、紫荆杂志社承办的"2025香港国际中医药大会"在香港会议 展览中心盛大启幕。本次大会以"推动中医药高质量走向世界"为主题，汇聚来自中国内地及 港澳台地区、东南亚等"一带一路"沿线国家和地区的近500位专家学者、行业领袖及企业代 表，包括20余位院士、国医大师、岐黄学者，以及超过130家参展机构。大会通过稀有中药 材展览、中医药文化体验、中医药产品展销、名医讲座等多元形式，展现中医药的实用价值 与发展前景，吸引"政、产、学、研"各界代表参与，共商中医药国际化发展的新路径与新机 遇。 大会开幕式现场 大会以近半小时的港式"八段锦"暨太极养生六式功法、坐式养生功法作为开场。表演者将八 段锦、太极融入现代都市生活场景，为繁忙的"上班族"提供了简易的健身方式，现场观众反 应热烈，并纷纷跟学模仿，展现了中医文化在日常健康管理中的实用性。会场同步开设诸多 名企展区，展出多种珍贵中药材，配以图文解说，帮助参观者深入了解药材特性与临床应 用，为大家提供了广阔的交流平台。 全国政协副主席梁振英， ...

Core Insights - The Tianjin Municipal Medical Procurement Center has initiated a price risk management program targeting 104 traditional Chinese medicine products, highlighting the increasing pressure on pricing in the industry [2][6] - A strict pricing control system has been established, categorizing products into yellow and red labels based on their price relative to the lowest price of similar products, which could lead to suspension from the market if prices remain excessively high [2][6] - The traditional Chinese medicine market is undergoing significant changes as nearly 20 provinces have joined the price governance movement, indicating a nationwide trend towards price adjustments [2][6] Pricing Control Measures - The new pricing control measures classify products with prices exceeding three times the lowest price as yellow label, and those exceeding five times as red label, with a direct suspension for prices above ten times [2][6] - The focus of this governance is on the commonly used Da Huo Luo Wan, which has seen drastic price variations, with some brands priced as high as 200 yuan per box compared to around 40 yuan for others [2][3] Market Dynamics - Major traditional brands like Tong Ren Tang and Da Ren Tang have been able to maintain higher prices due to their use of premium raw materials, but they are now facing increased scrutiny and pressure to lower prices [3][4] - The market share of these brands is concentrated in regions outside Tianjin, with significant sales in provinces like Jiangsu and Hebei, indicating a potential vulnerability to price governance measures [4][6] Financial Performance - The financial performance of traditional Chinese medicine companies has been under pressure, with 36 companies reporting declines in profits in the first half of 2025, and notable drops in net profits for companies like Huasheng Technology and Weikang Pharmaceutical [7][8] - Tong Ren Tang reported a slight increase in revenue but a decrease in net profit, while Da Ren Tang's profit growth was largely due to one-time gains from asset sales [7][8] Industry Challenges - The complexity of traditional Chinese medicine, with its varied ingredients and production processes, complicates pricing governance, as it cannot be easily evaluated like chemical drugs [5][6] - There are concerns that strict price controls may lead to a decline in quality, as companies may be forced to cut costs to comply with pricing regulations [5][6] Future Directions - Experts suggest that establishing a pricing evaluation system that considers raw material costs, production complexity, and clinical value is essential for balancing price governance and maintaining quality [9][10] - The case of Da Huo Luo Wan illustrates the need for a value-based pricing system rather than simple price cuts, aiming to benefit patients while ensuring the sustainability of quality products [10]

Core Insights - The Chinese traditional medicine industry is experiencing significant growth driven by favorable policies and increasing market demand, with the market size expected to reach 1.05 trillion yuan in 2024, a year-on-year increase of 11.6% [1][3] - The industry is facing two major opportunities: policy dividends and market explosion, with a focus on balancing tradition and innovation [3][21] Policy and Market Dynamics - The government has introduced several policies to support the development of the traditional Chinese medicine industry, including the "Opinions on Improving the Quality of Traditional Chinese Medicine" and the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry" [3][4] - The market demand for traditional Chinese medicine is increasing due to rising health awareness and spending among consumers, particularly in areas such as aging, sub-health management, and chronic disease treatment [3][17] Quality Control and Innovation - Leading companies are enhancing quality control across the entire supply chain, with examples like Tong Ren Tang establishing a traceability system for medicinal materials and Guangzhou Pharmaceutical Group utilizing blockchain technology [4][19] - Companies are focusing on product innovation and adapting traditional formulas to meet contemporary health needs, with a strong emphasis on maintaining quality through traditional methods [6][10] Digital Transformation and E-commerce - The integration of digital technologies is crucial for the pharmaceutical industry, with companies like JD Health playing a significant role in transforming traditional medicine through e-commerce and data analytics [13][14] - The shift towards online platforms is helping traditional medicine brands reach younger consumers and adapt to changing market dynamics [10][13] Global Expansion and Future Directions - The internationalization of traditional Chinese medicine is becoming a key growth area, with products being registered in numerous countries and regions, reflecting a growing global acceptance [15][19] - Companies are focusing on three main strategic directions: deepening research and development, expanding into the "Chinese medicine +" health ecosystem, and accelerating digital integration [15][21]

Core Viewpoint - The announcement of a mid-year cash dividend by the company reflects its strong operational performance and commitment to shareholder returns, marking the first mid-year dividend since its listing [1][2]. Dividend Distribution - The company will distribute a cash dividend of 0.39 yuan per share, totaling over 411 million yuan, based on a total share capital of 1,054,568,442 shares, to be paid on September 26 [1]. - Cumulatively, the company has distributed over 7.9 billion yuan in dividends and repurchased shares worth over 1.7 billion yuan since its listing in 2016 [2]. - The company maintained a consistent dividend policy even during challenging times, with notable dividends in 2019 and 2022, showcasing its commitment to shareholder returns [2]. Industry Comparison - Compared to peers, the company's mid-year dividend of 0.39 yuan per share is positioned at a relatively high level within the industry, with a dividend yield of 2.52%, surpassing several competitors [3]. - Other pharmaceutical companies have also announced mid-year dividends, indicating a trend towards increased cash dividends in the sector [3]. Financial Performance - The company's solid dividend policy is supported by strong operational performance, with healthy cash flow from operating activities providing a robust financial foundation for the dividend [4]. - The company is expanding its portfolio in high-tech areas such as chemical drugs, biological drugs, and vaccines, with a total of 457 valid patents and 209 products under development [4]. Corporate Governance and Social Responsibility - The company's consistent cash dividend policy reflects its governance quality and commitment to attracting long-term investors [5]. - The company has engaged in social responsibility initiatives, sponsoring public welfare activities for 18 years and contributing over 32 billion yuan in taxes, demonstrating its commitment to societal value [6][7].

Core Viewpoint - The announcement details the progress of guarantees provided by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for its subsidiary Kunming Pharmaceutical Group, specifically for its wholly-owned subsidiaries [1][3][7] Summary by Sections Guarantee Overview - The total guarantee amount for the subsidiaries is set at 14 million RMB, with a cumulative guarantee balance of 39.8 million RMB already provided [1][2] - The guarantee is within the previously estimated limits and does not involve any counter-guarantees [2] Guarantee Progress - The guarantees are aimed at supporting the operational and business development needs of Kunming Pharmaceutical Group's subsidiaries [4] - The guarantee plan was approved during the board meeting and the annual shareholders' meeting [3] Company Information - The guaranteed companies, Xishuangbanna Dai Medicine and Dali Huirui Pharmaceutical, have a good credit status and are not listed as dishonest executors [5] Guarantee Agreement Details - The guarantee period lasts for three years from the date of the agreement [6] - Other shareholders of Dali Huirui have signed a maximum guarantee contract, with individual shareholders assuming joint guarantee responsibilities [6] Necessity and Reasonableness of Guarantee - The guarantees are deemed necessary to meet the production and operational needs of Kunming Pharmaceutical Group for 2025, enhancing financing efficiency and reducing costs [6] - The company maintains oversight of the financial status and cash flow of the guaranteed subsidiaries, ensuring manageable risk [6] Cumulative Guarantee Amounts - As of the announcement date, the total external guarantee balance for Kunming Pharmaceutical Group and its subsidiaries is 122.2 million RMB, representing 2.33% of the latest audited net assets [6] - The total guarantee limit for 2025 for Kunming Pharmaceutical Group and Tian Shi Li Pharmaceutical Group is 1.35615 billion RMB, accounting for 6.81% of the latest audited net assets [7]

股票代码：000999 股票简称：华润三九 编号：2025—075 华润三九医药股份有限公司 关于控股子公司昆药集团担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 一、担保情况概述 1. 担保事项履行的相关程序 为适应昆药集团及其相关下属公司业务发展需要，满足相关公司融资担保需求，经华润 三九董事会 2025 年第五次会议及 2024 年年度股东会审议通过，2025 年度昆药集团及其下 属子公司预计为昆药集团下属子公司不超过人民币 4.5615 亿元的银行融资授信业务提供连 被担保人：昆药商业西双版纳傣医药经营有限公司（以下简称"版纳傣医药"）、大理 辉睿药业有限公司（以下简称"大理辉睿"）。上述被担保人为华润三九医药股份有限 公司（以下简称"华润三九"）控股子公司昆药集团股份有限公司（以下简称"昆药集 团"）下属全资子公司昆药集团医药商业有限公司（以下简称"昆药商业"）的全资及控 股子公司，不存在关联担保。 本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为 1,400 万元，累计已实际为其提供的担 ...

Core Viewpoint - The approval of the innovative drug "普佑克" (recombinant human urokinase) for treating acute ischemic stroke (AIS) marks a significant breakthrough in China's thrombolytic therapy for stroke, reflecting the country's push for innovation in biomedicine [1][2]. Company Summary - Tian Shi Li Pharmaceutical Group has received approval from the National Medical Products Administration for its innovative drug "普佑克," which is now indicated for AIS treatment, following its previous approval for acute ST-segment elevation myocardial infarction [1]. - The drug has demonstrated a lower risk of bleeding compared to competitors, as evidenced by clinical trials published in reputable medical journals [1]. - The company has 31 innovative drug projects in development, including advancements in cell and gene therapy and bispecific antibodies, with three products recently receiving clinical approval [2]. Industry Summary - The biopharmaceutical industry in China is experiencing unprecedented growth, with a 59% year-on-year increase in the number of innovative drugs approved in the first half of 2025, totaling 43 approvals, of which 93% are domestic innovations [3]. - The integration of Tian Shi Li into China Resources Sanjiu is expected to enhance its capabilities in key therapeutic areas, optimizing its research and development pipeline [3]. - The Chinese government has implemented supportive policies for the development of innovative drugs, creating a favorable environment for the biopharmaceutical sector [3].

Core Viewpoint - The China Listed Companies Association has released the "2025 Cash Dividend Ranking" based on the objective data of cash dividends from A-share listed companies in 2024, highlighting the strong cash return capabilities of companies like China Resources Sanjiu [1] Group 1: Dividend Policy and Performance - China Resources Sanjiu has been recognized for its stable high dividend payout policy, reflecting market acknowledgment of its continuous cash return ability [1] - In 2024, the company distributed a total of 1.695 billion yuan in dividends, accounting for 50.34% of its net profit attributable to shareholders [1] - The company has implemented three cash dividend distributions in the past year, totaling nearly 2.5 billion yuan [1] Group 2: Financial Metrics - Since its listing in 2000, China Resources Sanjiu has returned a total of 10.071 billion yuan to shareholders, which is 605% of the actual fundraising amount of 1.666 billion yuan [2] - In the first half of 2025, the company achieved operating revenue of 14.810 billion yuan, a year-on-year increase of 4.99%, and a net profit of 1.815 billion yuan [2] Group 3: Corporate Social Responsibility and Industry Impact - The company emphasizes social responsibility by creating stable returns for investors while promoting ecological protection and public health [2] - China Resources Sanjiu has established over 30 standardized Chinese medicinal herb planting bases, covering more than 300,000 acres, ensuring quality through traceability [2] - The company is committed to intelligent and low-carbon transformation in manufacturing, integrating new information technologies into the entire drug manufacturing process [3]